Inhibikase Therapeutics, Inc.
IKT
$1.44
$0.032.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.93M | -9.92M | -13.68M | -12.13M | -5.78M |
| Total Depreciation and Amortization | 23.70K | 24.20K | 12.70K | 6.60K | 6.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.46M | 3.85M | 8.23M | 7.91M | 148.00K |
| Change in Net Operating Assets | -2.15M | 466.80K | 1.33M | -1.13M | 742.40K |
| Cash from Operations | -10.59M | -5.57M | -4.10M | -5.35M | -4.88M |
| Capital Expenditure | 0.00 | 0.00 | -13.40K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -28.75M | 9.84M | 21.07M | -38.76M | 2.53M |
| Cash from Investing | -28.75M | 9.84M | 21.05M | -38.76M | 2.53M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 250.90K | 31.80K | -- | 99.68M | 182.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -385.10K | -- | -- | -- | -- |
| Cash from Financing | -134.10K | 31.80K | -- | 99.68M | 182.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -39.47M | 4.30M | 16.95M | 55.58M | -2.17M |